Histogenics Corporation to Host Investor Day on June 19, 2018
May 31, 2018 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored...
Histogenics Corporation Announces First Quarter 2018 Financial and Operating Results
May 10, 2018 06:30 ET
|
Histogenics Corporation
‒ Top-line Superiority Data from NeoCart® Phase 3 Clinical Trial and Potential Biologics License Application Submission on Track for Third Quarter of 2018 ‒‒ Initiation of Phase 3 Clinical Trial in...
Histogenics Corporation to Present at Upcoming Investor Conferences
March 28, 2018 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017
March 15, 2018 06:00 ET
|
Histogenics Corporation
NeoCart® Top-line Phase 3 Clinical Trial Data and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018 NeoCart Licensing Agreement with MEDINET Co. Ltd. Provides...
Histogenics to Showcase NeoCart® at American Academy of Orthopedic Surgeons and Orthopedic Research Society 2018 Annual Meetings
March 02, 2018 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
Histogenics Corporation to Present at Upcoming Investor Conferences
February 20, 2018 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
January 25, 2018 16:05 ET
|
Histogenics Corporation
WALTHAM, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the closing of its...
Histogenics Corporation and MEDINET Co., Ltd Enter Into Licensing Agreement for Development and Commercialization of NeoCart for the Japanese Market
December 21, 2017 06:00 ET
|
Histogenics Corporation
– Transaction Terms Include a $10 Million Up-front Payment with a Potential of $87 Million in Total Milestones, and Tiered Royalties on Sales ‒ ‒ Japanese Cartilage Repair Market is Large and Growing...
Histogenics Corporation Announces Third Quarter 2017 Financial and Operating Results
November 09, 2017 06:30 ET
|
Histogenics Corporation
Top-line, 1-year Superiority Data for NeoCart® Phase 3 Clinical Trial and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018 Company to Host Conference Call...
Histogenics Corporation Promotes Stephen Kennedy to Executive Vice President & Chief Operating Officer
October 12, 2017 09:00 ET
|
Histogenics Corporation
WALTHAM, Mass., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the...